Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Pulsed Dose Chemotherapy for R/M HNSCC
NCT06052839Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, carboplatin, paclitaxel in head and neck squamous cell carcinoma (HNSCC). Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06052839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052839.